Pzizer and BioNTech announced Tuesday they are starting tests of a revamped COVID-19 vaccine designed to target the omicron variant.
The study will be made up of healthy adults ages 18 to 55. About 1,400 volunteers will participate.
We wish them luck. And we see this as a sign of what the future may hold.
For just as the news of the vaccine trial was released, The Washington Post reported a new strain of omicron variant called BA.2.
It's been detected in 40 countries so far. And three cases have turned up in Houston.
It's similar to omicron, but harder to detect with a polymerase chain reaction -- or PCR -- test. There is no evidence yet it causes a more sever infection than the original omicron.
Over the years, there have been several strains of the flu. Right now, the seasonal flu vaccine varies from year to year based on what scientist predict will be the dominant strain.
We can see something similar in COVID-19. And that would be a good thing. It would mean the virus has become much more manageable. Our world would return to some sense of normalcy.
We aren't there yet. But we can hope.